Wisner Baum's Legal Actions Question FDA's Authority Over Spinal Cord Stimulators
Wisner Baum's Legal Actions Question FDA's Authority Over Spinal Cord Stimulators
National law firm Wisner Baum LLP has initiated numerous lawsuits targeting the manufacturers of spinal cord stimulators (SCS), asserting that these devices, purportedly designed to relieve chronic pain, have instead inflicted severe harm on patients. The complaints arise from allegations that these medical devices are not only ineffective but that they also possess serious risks, including electric shocks, heightened pain, and neurological damage.
These lawsuits, accumulating across the United States, have been brought against key industry players, including Abbott Laboratories, Boston Scientific, Medtronic, and Nevro. These legal actions not only aim to seek justice for the harmed individuals but also raise significant questions about the regulatory framework governed by the U.S. Food and Drug Administration (FDA).
Questioning the Regulatory Framework
The core of this litigation is a spinal cord stimulator system initially deemed safe and effective by the FDA back in 2001. The allegations suggest that while the device has undergone numerous modifications over the years, it has continuously been marketed as FDA-approved without undergoing new clinical trials. According to Behram Parekh, an attorney representing the plaintiffs, there is a concerning gap where regulatory oversight has failed to adapt to the evolving nature of medical devices. "The FDA's capacity to assess each modification appears increasingly inadequate, given the high stakes involved with these patient-facing devices," Parekh stated.
Patients have reported grievous effects after implantation, which include:
- - Painful electric shocks
- - Loss of the therapeutic effect
- - Device malfunctions and unforeseen shutdowns
- - Surgical complications and infections
- - Repeat surgeries and ultimately device removals
Many patients have expressed their disappointment, having been assured that these devices would provide lasting relief from chronic pain. Instead, they have experienced minimal to no benefits, often accompanied by new or exacerbated symptoms. Parekh noted, "The disparity between patients’ expectations and their actual experiences is quite remarkable. These are individuals desperate for non-opioid pain relief after failing to find alternative solutions."
The Issue of Cumulative Changes
Central to the legal claims is the fact that spinal cord stimulators approved decades ago have undergone countless modifications—often without the need for fresh clinical trials or rigorous regulatory evaluation. Manufacturers appear to utilize the FDA's premarket approval (PMA) supplement process to make substantial changes, including alterations to software, battery systems, and therapy delivery methods. Despite these modifications, the devices remain marketed under the guise of FDA approval, raising concerns among plaintiffs that they may be untested or potentially unsafe. Parekh remarked, "Manufacturers can label each modification as a minor shift, yet the cumulative changes may result in a product that bears little resemblance to its original form."
A Nationwide Pattern of Harm
The grievances extend beyond isolated incidents, with numerous states and individuals echoing similar concerns. Patients frequently undergo a trial implantation, only to find themselves facing serious complications that lead to further surgeries—a cycle of disappointment and health risks.
The litigation hopes to shed light on the broader implications of this regulatory structure, particularly whether the existing FDA approval process can adequately protect patients, especially as manufacturers continue to innovate and alter their products. Comparable international agencies, such as Australia's Therapeutic Goods Administration, have taken proactive measures in reviewing medical devices, emphasizing post-market evaluations and stricter requirements.
“In public trust lies the demand for accountability from medical device companies and the regulatory bodies that oversee them,” Parekh said. “Patients must not be deprived of justice simply because a device passed through a deficient approval process, especially given the extensive modifications that have occurred since.”
About Wisner Baum
Wisner Baum is distinguished as a prominent plaintiffs' law firm recognized for its fierce advocacy, especially for individuals harmed by corporate misconduct and dangerous products. Through its commitment to justice and accountability, Wisner Baum seeks to support vulnerable patients and uphold rigorous standards in medical device regulations.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.